Shedding of ctDNA, radiomics assessment of tumor disease volume (TDV), and concordance of mutations (mut) in synchronous liquid and tumor biopsies in metastatic breast cancer (MBC).

被引：0
|
作者：
Papakonstantinou, Andri
Gonzalez-Medina, Alberto
Matito, Judit
Ligero, Marta
Ruiz-Pace, Fiorella
Sunol, Anna
Rivero, Joaquin
Fasani, Roberta
Cruellas, Mara
Peg, Vicente
Borrell, Maria
Pimentel, Isabel
Munoz, Santiago Escriva De Romani
Gelpi, Judith Balmana
Nuciforo, Paolo
Dienstmann, Rodrigo
Saura, Cristina
Perez-Lopez, Raquel
Oliveira, Mafalda
Vivancos, Ana
机构：
[1] Karolinska Inst & Breast Canc Grp, Vall Hebron Inst Oncol VHIO, Dept Oncol Pathol, Barcelona, Spain
[2] Vall Hebron Inst Oncol VHIO, Canc Genom Grp, Barcelona, Spain
[3] Vall Hebron Inst Oncol VHIO, Radi Grp, Barcelona, Spain
[4] Vall Hebron Inst Oncol VHIO, Oncol Data Sci ODysSey Grp, Barcelona, Spain
[5] Vall Hebron Inst Oncol VHIO, Breast Canc Grp, Barcelona, Spain
[6] Vall dHebron Univ Hosp, Breast Canc Ctr, Breast Surg Unit, Barcelona, Spain
[7] Vall Hebron Inst Oncol VHIO, Mol Oncol Grp, Barcelona, Spain
[8] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept & Breast Canc Grp, Barcelona, Spain
[9] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[10] Vall dHebron Inst Oncol, Clin Canc Genet & Breast Canc Grp, Barcelona, Spain
[11] Vall Hebron Inst Oncol, Barcelona, Spain
[12] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1086
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study
    Goetz, Matthew P.
    Gal-Yam, Einav
    Stover, Daniel
    Sammons, Sarah L.
    Graff, Stephanie L.
    Wang, Grace
    Cristofanilli, Massimo
    Riordan, Gary
    Sloane, Hillary S.
    Carroll, Dominic
    Plourde, Paul V.
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [42] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study
    Damodaran, Senthil
    Moore, Halle
    O'Sullivan, Ciara C.
    Plourde, Paul V.
    Riordan, Gary
    Sloane, Hillary S.
    Tripathy, Debu
    Carroll, Dominic
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [43] Exploratory circulating tumor DNA (ctDNA) analysis in HR+/ HER2-metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02
    Rugo, H. S.
    Zhang, Y.
    Marme, F.
    Schmid, P.
    Cortes, J.
    Tolaney, S. M.
    Tang, S.
    Yoon, O. K.
    Verret, W.
    Das Thakur, M.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S391 - S392
  • [44] Comparison of nextgeneration sequencing (NGS) results from the cerebrospinal fluid, peripheral blood, and systemic metastatic tumor tissue of patients with metastatic breast cancer (MBC) and leptomeningeal disease (LMD)
    Huppert, Laura
    Her, Lindy
    Hodgdon, Christine
    Brain, Susie
    Simmons, Carol
    Chien, Jo
    Majure, Melanie
    Rugo, Hope
    Magbanua, Mark Jesus
    Balassanian, Ron
    Melisko, Michelle
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)
    Meisel, Jane
    Sammons, Sarah L.
    Shanahan, Kelly
    Pluard, Timothy
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.
    Chi, Kim N.
    Barnicle, Alan
    Sibilla, Caroline
    Lai Zhongwu
    Corcoran, Claire
    Williams, Andrew J.
    Barrett, Carl J.
    Adelman, Carrie A.
    Qiu Ping
    Easter, Ashley
    Dearden, Simon
    Harrington, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [47] Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)
    Mazzeo, R.
    Bortot, L.
    Michelotti, A.
    Buriolla, S.
    Palmero, L.
    Franzoni, A.
    Bertoli, E.
    Targato, G.
    Allegri, L.
    Da Ros, L.
    Alberti, M.
    Di Nardo, P.
    Bonotto, M.
    Sodde, S.
    Belletti, B.
    Spazzapan, S.
    Baldassarre, G.
    Damante, G.
    Gerratana, L.
    Puglisi, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S492 - S493
  • [48] PIK3CA and ESR1 mutations detected in circulating tumor DNA (ctDNA) are predictive factors for late-line hormone-based therapies in ER+/HER2-metastatic breast cancer (MBC)
    Chen, Tom Wei-Wu
    Dai, Ming-Shen
    Chang, Dwang-Ying
    Lin, Ching-Hung
    Chen, I-Chun
    Wang, Ming-Yang
    Huang, Ling-Yi
    Hsu, An
    Zhuo, De-Wei
    Tan, Kien Thiam
    Lu, Yen-Jung
    Chang, Shu-Han
    Cheng, Ann-Lii
    Lu, Yen-Shen
    CANCER RESEARCH, 2020, 80 (04)
  • [49] Associations between plasma Interleukin 2 (IL-2) and HER2 expression in circulating tumor cell (CTC) and MYC alterations in circulation tumor DNA (ctDNA) open a new insight on immune microenvironment for patients with metastatic breast cancer (MBC)
    Zhang, Q.
    Gerratana, L.
    Zhang, Y.
    Flaum, L.
    Shah, A.
    Davis, A.
    Behdad, A.
    Gradishar, W.
    Platanias, L.
    Cristofanilli, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [50] Sensitive tumor detection, accurate quantification, and ER subtyping using low-pass methylome of liquid biopsy samples from patients (pts) with metastatic breast cancer (mBC)
    Paoli, Marta
    Nardone, Agostina
    Galardi, Francesca
    Biagioni, Chiara
    Romagnoli, Dario
    De Luca, Francesca
    Franceschini, Gian Marco
    Migliaccio, Ilenia
    Pestrin, Marta
    Sanna, Giuseppina
    Risi, Emanuela
    Livraghi, Luca
    Moretti, Erica
    Biganzoli, Laura
    Malorni, Luca
    Demichelis, Francesca
    Benelli, Matteo
    CANCER RESEARCH, 2024, 84 (09)
12345